125 related articles for article (PubMed ID: 12182172)
1. New medication recommended for Parkinson's disease.
Levenson D
Rep Med Guidel Outcomes Res; 2001 Jun; 12(13):7-9. PubMed ID: 12182172
[No Abstract] [Full Text] [Related]
2. [Hallucinations in Parkinson's disease].
Moser A; Hagenah J; Kömpf D
Nervenarzt; 2003 Apr; 74(4):376-85, quiz 385-6. PubMed ID: 12707709
[TBL] [Abstract][Full Text] [Related]
3. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
4. Clozapine for psychosis in Parkinson's disease.
Pfeiffer RF; Kang J; Graber B; Hofman R; Wilson J
Mov Disord; 1990; 5(3):239-42. PubMed ID: 2388641
[TBL] [Abstract][Full Text] [Related]
5. Parkinson's: integrating the primary and secondary care guidelines.
Macmahon D; Brooks D; Smith R
Practitioner; 2000 Apr; 244(1609):370-8. PubMed ID: 10892059
[No Abstract] [Full Text] [Related]
6. Clozapine withdrawal symptoms in a Parkinson's disease patient.
Zesiewicz TA; Borra S; Hauser RA
Mov Disord; 2002 Nov; 17(6):1365-7. PubMed ID: 12465085
[TBL] [Abstract][Full Text] [Related]
7. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
8. Dopamine agonists for Parkinson's disease.
Sharma J; MacMahon D; Stewart D
Lancet; 2003 Jan; 361(9351):84; author reply 84. PubMed ID: 12517504
[No Abstract] [Full Text] [Related]
9. Parkinson's disease.
Clarke C; Moore AP
Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738
[No Abstract] [Full Text] [Related]
10. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
Kondo T
J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
[TBL] [Abstract][Full Text] [Related]
11. Parkinson's disease.
Clarke C; Moore A
Clin Evid; 2002 Dec; (8):1370-85. PubMed ID: 12603943
[No Abstract] [Full Text] [Related]
12. [Drug therapy in Parkinson's disease].
Jansen EN
Ned Tijdschr Geneeskd; 1999 Apr; 143(15):817. PubMed ID: 10347646
[No Abstract] [Full Text] [Related]
13. Medical hazards of the internet: gambling in Parkinson's disease.
Larner AJ
Mov Disord; 2006 Oct; 21(10):1789. PubMed ID: 16941457
[No Abstract] [Full Text] [Related]
14. DA agonists -- ergot derivatives: lisuride: management of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S74-8. PubMed ID: 12211144
[No Abstract] [Full Text] [Related]
15. Future therapies for Parkinson's disease.
Hauser RA; Lyons KE
Neurol Clin; 2004 Oct; 22(3 Suppl):S149-66. PubMed ID: 15501363
[No Abstract] [Full Text] [Related]
16. Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis.
Baker WL; Silver D; White CM; Kluger J; Aberle J; Patel AA; Coleman CI
Parkinsonism Relat Disord; 2009 May; 15(4):287-94. PubMed ID: 18774743
[TBL] [Abstract][Full Text] [Related]
17. DA agonists -- non-ergot derivatives: apomorphine: management of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S83-9. PubMed ID: 12211146
[No Abstract] [Full Text] [Related]
18. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
Mercuri NB; Bernardi G
Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
[TBL] [Abstract][Full Text] [Related]
19. Motor complications of Parkinson's disease.
Martignoni E; Riboldazzi G; Calandrella D; Riva N
Neurol Sci; 2003 May; 24 Suppl 1():S27-9. PubMed ID: 12774208
[TBL] [Abstract][Full Text] [Related]
20. [Medicinal treatment of idiopathic Parkinson's disease].
Klockgether T
Nervenarzt; 2003 Mar; 74 Suppl 1():S12-21. PubMed ID: 12624679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
